Medirom Reports Q1 2026 KPIs: Mixed Salon Trends, World ID Deployment Progresses, HealthTech Grows
MRM sits 33% above its 52-week low of $0.9 on light trading volume (0.2× avg).
Summary
Medirom Healthcare Technologies released its Q1 2026 operational update, highlighting growth in its World ID and HealthTech segments while its core salon business saw declining customer numbers offset by higher revenue per customer and strategic staffing changes.
Key Events · Earnings and Guidance · MRM
-
Salon Business Update
Revenue per customer increased 7.7% year-over-year to 7,822 JPY, and the operating ratio improved. However, the number of salons decreased by 21 and total customers by 13.9% year-over-year.
-
Hybrid Staffing Model Expansion
The proportion of independent contractors reached 53% of the total workforce by Q1 2026, a strategic shift aimed at improving motivation, retention, and profitability.
-
World ID Deployment Progress
The strategic partnership with Tools for Humanity resulted in approximately 31,000 total World ID verifications by the end of Q1 2026, with plans for mid-term expansion to 3,000 locations.
-
HealthTech Business Growth
The Lav® HealthTech business expanded its partnerships to 106 insurers (+8.2% year-over-year) and increased cumulative users to 13,226 (+3,525 year-over-year), leveraging salon therapists as coaches.
Analysis · MRM · Trade & Services
Medirom Healthcare Technologies reported its Q1 2026 Key Performance Indicators, showing mixed results in its core salon business with declining salon and customer counts but improved revenue per customer and operating efficiency. The company continues to expand its World ID partnership with 31,000 total verifications and is growing its HealthTech (Lav®) segment, which leverages synergies with its salon therapists. These strategic initiatives are crucial for the micro-cap company's long-term growth and profitability.
At the time of this filing, MRM was trading at $1.20 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.90 to $4.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.